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Introduction
Evidence-based medicine was presented as a new
paradigm in the teaching and practice of medicine
that stresses the examination of evidence from clinical
research and discourages clinical decision-making
based on intuition, unsystematic clinical experience
and pathophysiologic rationale.1 The development
and implementation of evidence-based clinical prac-
tice guidelines (CPGs), one of themost promising and
eﬀective tools for improving the quality of care, was
clearly linked to this movement.2,3 The main objec-
tives of CPGs are to standardise procedures, reduce
unjustiﬁed variations in clinical practice and change
physician behaviour to promote the use of inter-
ventions supported by the best evidence available.3–7
Several strategies have been described for the dis-
semination and implementation of CPGs once they
have been developed.4 The rapid expansion of com-
puter usage in health care in recent years has allowed
the development of computer-based CPGs.8–13 For
instance, the region of Catalonia (Spain) has a com-
puterised primary care system and the use of informa-
tion technology in routine practice is set to increase.
Indeed, the electronic medical record software has
recently incorporated the electronic version of CPGs
(e-CPGs) for the most common chronic disorders in
the population (hypercholesterolaemia, diabetesmellitus
type 2 and hypertension).14–16 This electronic version
includes the three key points that Grimshaw et al4
deﬁned for successful CPG dissemination and im-
plementation procedures: easy access to the e-CPG,
the use of reminders to guide the actions of healthcare
professionals and ﬁnally, useful feedback to inform
healthcare professionals about the appropriateness of
their actions.
Themain characteristic of the e-CPG system imple-
mented by the Catalan Institute of Health is that it is
linked to the electronic medical record system. This
innovation allows the generation of individualised
recommendations for the diagnosis, treatment, con-
trol andmanagement of disorders considering patient
characteristics. The e-CPG also includes information
on drug safety (e.g. interactions, secondary eﬀects)
and can be updated whenever new drugs or diagnostic
tests appear.
In addition, independently of e-CPG use, the con-
tract for family practitioners (FPs) has been ﬁnancially
incentivised based on the degree of control for these
chronic disorders.17 All FPs are able to activate the
software from a badge incorporated in the main page
of the electronic medical record system.
Despite the considerable amount of money spent
on e-CPG development and implementation, relatively
little attention has been paid to ensuring adherence to
e-CPG recommendations and success in reaching the
established primary care treatment goals. So far, no
single strategy eﬀectively ensures that e-CPGs are put
into practice.2,17–23 Moreover, most of the studies
conducted to ascertain the eﬀectiveness of implemen-
tation procedures and adherence to clinical guidelines
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Background The electronic medical records soft-
ware of the Catalan Institute of Health has recently
incorporated an electronic version of clinical prac-
tice guidelines (e-CPGs). This study aims to assess
the impact of the implementation of e-CPGs on the
diagnosis, treatment, control and management of
hypercholesterolaemia, diabetesmellitus type 2 and
hypertension.
Methods Eligible study participants are those aged
35–74 years assigned to family practitioners (FPs)
of the Catalan Institute of Health. Routinely col-
lected data from electronic primary care registries
covering 80% of the Catalan population will be
analysed using two approaches: (1) a cross-sectional
study to describe the characteristics of the sample
before e-CPG implementation; (2) a controlled
before-and-after study with 1-year follow-up to
ascertain the eﬀect of e-CPG implementation. Patients
of FPs who regularly use the e-CPGs will constitute
the intervention group; the control group will
comprise patients assigned to FPs not regularly
using the e-CPG. The outcomes are: (1) suspected
and conﬁrmed diagnoses, (2) control of clinical
variables, (3) requests for tests and (4) proportions
of patients with adequate drug prescriptions.
Results This protocol should represent a repro-
ducible process to assess the impact of the im-
plementation of e-CPGs. We anticipate reporting
results in late 2013.
Conclusion This project will assess the eﬀective-
ness of e-CPGs to improve clinical decisions and
healthcare procedures in the three disorders ana-
lysed. The results will shed light on the use of
evidence-based medicine to improve clinical prac-
tice of FPs.
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have been conducted using a single disorder and
selected FP samples.8–12
We propose a study to ascertain the eﬀect on FP
habits of implementing the e-CPGs in a population-
based sample of records obtained from routinely
collected general practice data. This population-based
approach will allow us to include not only individuals
with a wide range of severity of hypercholesterolaemia,
diabetes mellitus type 2 and hypertension, but also
those who do not meet all criteria for diagnosis but
are at high risk of developing a disorder (suspected
diagnosis). Finally, the sample size of the study will
provide suﬃcient statistical power to estimate the
eﬀect of CPG implementation.
We hypothesise that a complex e-CPG integrated at
several appropriate points in an electronic medical
record (e.g. reminders and feedback) could increase
FPs’ access to e-CPG recommendations and achieve
better results because complex assessments can be
performed quickly. At the same time, point-of-care
implementation will achieve consistent exposure to e-
CPG recommendations and the evidence behind it,
which should reduce variability in clinical practice
regarding the control of clinical variables, and the
diagnosis, treatment and management of hyper-
cholesterolaemia, diabetes mellitus type 2 and hyper-
tension.
Objectives
The main goal of this study is to assess the impact of
the implementation of an e-CPG software for the
control of clinical variables, and the diagnosis, treat-
ment and management of hypercholesterolaemia,
diabetes mellitus type 2 and hypertension.
Methods
Electronic clinical practice guidelines
The combination of a successful and ﬂexible electronic
medical record and rigorous, evidence-based e-CPGs
may be ideal for introducing evidence-based practice
into a wide variety of environments. The clinical guide-
lines for the prevention of hypercholesterolaemia,14
diabetes mellitus type 215 and hypertension16 to be used
in the present study were developed between 2007 and
2011. To encourage the use of the newly available
resources, oﬃcial supporting materials were dissem-
inated in routine seminars held in all primary care
centres of the Catalan Institute of Health.24
The incorporation of the e-CPG software through-
out the medical record includes a screen that inte-
grates the clinical information of patients with all
preventive activities described in the CPG.14–16 The
e-CPG is a two-level interactive software that guides
the FPs’ actions through pop-up windows with re-
minders. FPs are free to choose the level of interaction
they want to work with. In the ﬁrst level, the alert
system recommends changes towards the diagnosis,
treatment, control and management of each disorder
(i.e. hypercholesterolaemia, diabetes mellitus type 2
and hypertension). In the second level, the FPs have
access to the algorithms included in e-CPGs that point
to the best evidence-based activities regarding diag-
nosis, treatment and follow-up in each particular case
(Figure 1).
Additionally, the software assesses the FP’s actions
concerning: (1) the accuracy of diagnosis and phar-
macological treatment; (2) the control of clinical
variables; and (3) the appropriateness of follow-up
undertaken, including tests performed. Each of the
three items is colour-coded. The classiﬁcation colours
are white (patient values are correctly controlled),
yellow (alerting FP to suspected diagnoses, such as a
patient with systolic blood pressure 140 mmHg in a
single measurement and without diagnosis of hyper-
tension) and red (poorly controlled values, such as a
diagnosis of diabetes mellitus type 2 and glycated
haemoglobin > 7%). Two speciﬁc items referring to
diagnosis and follow-up could also appear in red: (1) a
missing primary or secondary prevention diagnosis
for a patient whose values fulﬁl all the CPG criteria
(e.g. a record with two total cholesterol determina-
tions > 250 mg/dl and no diagnosis of hypercho-
lesterolemia, or no secondary prevention diagnosis
in the medical record of an individual with history of
cardiovascular disease); (2) missing follow-up such as
relevant tests for a particular diagnosis (e.g. micro-
albuminuria test) not performedwithin the last year in
a patient with diabetes mellitus) (Figure 1).
Tables 1 and 2 include the diagnoses recognised and
treatments recommended by e-CPGs, respectively.
Study setting and selection of
participants
The timeline of this project follows the e-CPG im-
plementation process, which started in March 2010
with the hypercholesterolaemia guideline and ﬁnished
in September 2011 with hypertension and diabetes
guidelines.
We will analyse routinely collected data from elec-
tronic primary care registries corresponding to 279
primary care practices of the Catalan Institute of
Health in Catalonia, with a total population of more
than 2,800,000 patients aged 35–74 years (80% of the
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Catalan population). The volume of data guarantees
population representativeness.25 Eligible study partici-
pants are those aged 35–74 years at baseline, assigned
to FPs working 36 hours or more per week. Those
individuals who have changed their FP assignment
during the study periodwill be excluded. The protocol
Figure 1 Electronic clinical practice guidelines software interface for the control of clinical variables,
diagnosis, treatment andmanagement of hypercholesterolaemia, diabetesmellitus type 2 and hypertension.
COL, hypercholesterolemia; DM-RISC, diabetesmellitus type 2; HTA, hypertension; D, diagnosis; T, treatment;
S, standards for follow-up
Table 1 Diagnoses recognised by electronic clinical practice guidelines
International Disease
Classiﬁcation 10
Cardiovascular risk factors
Hypertension I10, I15
Diabetes mellitus type 2 E11
Hypercholesterolaemia E78
Cardiovascular diseases
Myocardial infarction I20, I21, I22, I23, I25
Stroke I60, I61, I62, I63, I64
Intermittent claudication I73.8, I73.9
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of the present study was approved by the Institut
d’Investigacio´ en Atencio´ Prima`ria Jordi Gol Clinical
Research Ethics Committee (authorisation number
P09/28). All the registries analysed are codiﬁed and the
investigators have no access to individual identiﬁers
for FPs or their patients.
The study includes two diﬀerentiated designs:
. A cross-sectional study to describe the characteristics
of the population-based sample before the e-CPGs
implementation (January 2006 to December 2009).
. A controlled before-and-after study with 1-year
follow-up to ascertain the eﬀect of e-CPGs im-
plementation.26 The patients will be divided into
intervention and control groups according to the
assigned FP and the number of times each FP
accesses the e-CPGs, considered as a proxy of the
use of these resources. Data will be collected in both
groups contemporaneously, using similar methods
before and after the intervention; therefore, all
individuals are expected to experience similar secu-
lar trends or sudden changes. We will divide the
sample in quartiles of FPs according to the number
of patients whose record adheres to the e-CPGs.
The intervention group will include the individuals
assigned to FPs who use the e-CPGs system regu-
larly (exposed, fourth quartile); the control group
will include those assigned to FPs who do not use
the CPGs regularly (non-exposed, ﬁrst to third
quartiles).
In June 2011, we analysed CPG adherence for hyper-
cholesterolaemia at 1 year.
The CPG adherence analysis for diabetes and hy-
pertension at 1 year and for hypercholesterolaemia at
2 years was performed in June 2012.
Outcome measures
Information about the beneﬁts of this implementation
strategy will be described regarding patients and FPs.
First, outcomeswill be expressed as: (1) control of clinical
variables (e.g. cholesterol, glycated haemoglobin, blood
pressure); (2) suspected and/or conﬁrmed diagnoses;
(3) proportions of patients with appropriate drug
prescriptions; and (4) requests for tests (Tables 3–5).
Table 2 Treatments recommended by electronic clinical practice guidelines
Hypercholesterolemia ATC
Codes
Diabetes mellitus
type 2
ATC
Codes
Hypertension ATC
Codes
Atorvastatin C10AA05 Exenatide A10BX04 Losartan C09CA01
Lovastatin C10AA02 Liraglutide A10BX07 Valsartan C09CA03
Pravastatin C10AA03 Metformin A10BA02 Amplodipine C08CA01
Simvastatin C10AA01 Repaglinide A10BX02 Nifedipine C08CA05
Gemﬁbrozil C10AB04 Acarbose A10BF01 Diltiazem C08DB01
Colestyramin C10AC01 Miglitol A10BF02 Verapamil C08DA01
Saxagliptin A10BH03 Atenolol C07AB03
Sitagliptin A10BH01 Bisoprolol C07AB07
Vildagliptin A10BH02 Metoprolol C07AB02
Glibenclamide A10BB01 Chlorthalidone C03BA04
Glicazide A10BB09 Hydroclorthiazide C03AA03
Glimepiride A10BB12 Indapamide C03BA11
Gliquidone A10BB08 Captopril C09AA01
Pioglitazone A10BG03 Enalapril C09AA02
Lisinopril C09AA03
Peridopril C09AA04
Ramipril C09AA05
Trandolapril C09AA10
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All clinical variables will be measured following
standard methodology by healthcare professionals
(nurses and FPs) of the Catalan Institute of Health.
Bloodpressure ismeasuredwith aperiodically calibrated
sphygmomanometer with a cuﬀ adapted to upper arm
perimeter (young, adult, obese). Measurements are
performed after a 5-minute rest with individuals seated.
Two measurements were taken and the lower value
was recorded in the electronicmedical record. Blood is
withdrawn after at least 8 hours fasting, with less than
60 seconds’ duration. Lipid proﬁle, glycaemia and
glycated haemoglobin are determined following stan-
dardprocedures at laboratories accreditedby theCatalan
Institute of Health with external quality control.
For pharmacological indicators, patients are con-
sidered as previously untreated for the disorder diag-
nosed if they have nomedication prescriptions recorded
in the 3 months prior to the beginning of the study.
Process-of-care variables are also considered study
outcomes; all are aimed at assessing FP behaviour
changes for the 12 months following the implemen-
tation, and at 24 months for the hypercholesterolaemia
guidelines. The indicators of e-CPG usage are de-
scribed in Table 6.
Statistical analysis
Age-standardised prevalence will be determined for
each goal described in Tables 2–4. Individuals will be
categorised in 5-year age groups and a rough percent-
age or means calculated. This will be standardised by
the direct method, with reference to the European
population, for the purpose of the cross-sectional
analysis.27 These ﬁgures will be accompanied by the
95% conﬁdence interval and stratiﬁed by sex.
To analyse the data of the controlled before-and-
after design, categorical variables will be described as
percentages; continuous variables with normal distri-
bution will be described as mean and standard devi-
ation. Variables in which normal distribution cannot
be assumedwill be described asmedian and interquartile
range. Student’s t-test for independent samples, Mann–
Whitney U-test and chi-square tests will be used as
Table 3 Outcomes measured for hypercholesterolaemia according to CPG
recommendations
Conditions Goal (% of patients)
Suspected/conﬁrmed
diagnoses
Changes in FP attitude after CPG recommendation on hypercholesterolaemia
diagnosis
Changes in FP attitude after CPG alert on hypercholesterolaemia diagnosis
Patients with suspected hypercholesterolemia diagnosis conﬁrmed by FPs
after CPG alert
Registry of secondary prevention diagnosis in the electronic medical record of
individuals with CVD history
Control of clinical
variables
LDL cholesterol < 130 mg/dl in individuals on lipid-lowering treatment and
with no CVD history
LDL cholesterol < 100 mg/dl in individuals with CVD history or diabetes
mellitus type 2 and proteinuria
Requests for tests Estimation of coronary risk in men aged 35–74 and women aged 45–74, with
total cholesterol > 200 mg/dl (5.2 mmol/l) and with no CVD history
Estimation of coronary risk in individuals diagnosed with
hypercholesterolaemia in the follow-up
LDL cholesterol determination in the last year in individuals with and without
CVD history
Drug prescription
adequacy
Justiﬁed indication of pharmacologic treatment for hypercholesterolemia in
individuals with no CVD history and coronary risk > 10%
Adequacy of lipid-lowering drug selection in individuals with no CVD history
Changes in FP attitude after CPG recommendation on hypercholesterolaemia
treatment
Changes in FP attitude after CPG alert on hypercholesterolaemia treatment
CPG, clinical practice guideline; CVD, cardiovascular disease; LDL, low-density lipoprotein.
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appropriate to compare the clinical variables in the
exposed and non-exposed groups. Between-groups
analysis will be performed concerning the goals pro-
posed in the follow-up: (1) suspected and conﬁrmed
diagnoses; (2) control of clinical variables; (3) requests
for tests and (4) drug prescriptions adequacy; logistic
regression models adjusted for potential confounders
(i.e. variables signiﬁcantly diﬀerent between exposed
and non-exposed groups in the bivariate analysis) will
be used throughout.
Discussion
This studywill evaluate the implementation of three e-
CPGs that started in 2010 and concluded in 2011.
Population-based samples obtained from routinely
collected general practice data will be used for this
purpose. Indeed, notable information on quality of
care that can be used for health service planning can be
obtained from these data, with large potential use for
research provided that three conditions are met. First,
quality standards should be achieved; second, the
databases should meet the information governance
and research ethics guidelines; and ﬁnally, the data
management system should ensure the traceability of
data.28,29
Evaluation of e-CPGs implementation
In recent years, many evidence-based CPGs have been
developed for several disorders.30 In 2001 the Euro-
pean Union funded the Appraisal of Guidelines Re-
search & Evaluation (AGREE) Collaboration, which
created the AGREE Instrument to provide a frame-
work for assessing the quality of CPGs.31 Despite these
major investments by governments and scientiﬁc
societies to create and evaluate evidence-based CPGs,
the eﬀect of CPG implementation on healthcare
Table 4 Outcomes measured for diabetes mellitus type 2 according to CPG
recommendations
Conditions Goal (% of patients)
Suspected/conﬁrmed
diagnoses
Changes in FP attitude after CPG recommendation on diabetes mellitus type
2 diagnosis
Changes in FP attitude after CPG alert on diabetes mellitus type 2 diagnosis
Patients with suspected diabetes mellitus type 2 diagnosis conﬁrmed by FPs
after CPG alert
Control of clinical
variables
Glycated haemoglobin < 7% in individuals diagnosed with diabetes mellitus
type 2
LDL cholesterol < 130 mg/dl in individuals diagnosed with diabetes mellitus
type 2 and with no CVD history
LDL cholesterol < 100 mg/dl in individuals diagnosed with diabetes mellitus
type 2 with CVD history or proteinuria
Requests for tests Glycated haemoglobin determination in the last year in individuals diagnosed
with diabetes mellitus type 2
Electrocardiogram obtained in the last year in individuals diagnosed with
diabetes mellitus type 2
Inner eye test performed in the last year in individuals diagnosed with
diabetes mellitus type 2
Albumin-to-creatinin ratio or microalbuminuria test performed in the last
year in individuals diagnosed with diabetes mellitus type 2
Drug prescription
adequacy
Justiﬁed indication of pharmacologic treatment for diabetes mellitus type 2 in
individuals diagnosed with this disorder in the follow-up
Adequacy of hypoglycaemic drug selection
Changes in FP attitude after CPG recommendation on diabetes mellitus type
2 treatment
Changes in FP attitude after CPG alert on diabetes mellitus type 2 treatment
CPG, clinical practice guideline; CVD, cardiovascular disease; LDL, low-density lipoprotein.
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quality has been sparsely evaluated in population-
based samples.9,32–37 The use of routinely collected
data increases the sample representativeness and there-
fore the external validity of the study and provides an
accurate description of such eﬀect on FP atti-
tudes.28,29,38
Characteristics and limitations of the
study
Several limitations are inherent to outcomes research
in the evaluation of CPG adherence. First, the obser-
vational nature of the study makes the choice of the
study population and of the compared groups sus-
ceptible to selection bias.39 However, the representa-
tiveness of our sample is guaranteed because it includes a
broad sample of individuals aged 35–74 years from
Catalonia (80%of the population). To avoid temporal
trend bias we have chosen a controlled before-and-
after design. All individuals are expected to experience
similar secular trends or sudden changes because both
groups are contemporaneous and the methods used
before and after the intervention are similar.26 In this
study we will also evaluate the behaviour of FPs
towards three common disorders in the population
(hypercholesterolemia, diabetes and hypertension). All
three disorders meet the four conditions that make
them amenable to outcomes research: they have a
precise diagnostic deﬁnition and a diagnostic test with
high sensitivity and speciﬁcity, are reproducible among
diﬀerent individuals and locations, can be easily coded,
and are common in the population.39 Although e-CPGs
may help FPs to improve the quality of health care,
those with extensive experience in the ﬁeld of cardio-
vascular risk factorswill be less likely to rely upon these
instruments. Similarly, ﬁnancial incentives promoted
by the Catalan Institute of Health to all FPs for reaching
goals for population risk factor control may have an
eﬀect on the results. In addition, since we will do a
follow-up of one year for adherence to e-CPG indi-
cations for diabetes mellitus type 2 and hypertension,
some tests may not be completed during this period
(e.g. electrocardiograms in individuals diagnosedwith
hypertension). In these cases a similar a priori eﬀect
will be expected in both groups of patients assigned to
users and non-users of e-CPGs. Finally, the Hawthorne
eﬀect may alter our conclusions because FPs may
Table 5 Outcomes measured for hypertension according to CPG recommendations
Conditions Goal (% of patients)
Suspected/conﬁrmed
diagnoses
Changes in FP attitude after CPG recommendation on hypertension diagnosis
Changes in FP attitude after CPG alert on hypertension diagnosis
Patients with suspected hypertension diagnosis conﬁrmed by FPs after CPG
alert
Registry of hypertension severity in the electronic medical record of
individuals diagnosed with hypertension in the follow-up
Control of clinical
variables
Systolic blood pressure < 140 mmHg in individuals diagnosed with
hypertension
Diastolic blood pressure < 90 mmHg in individuals diagnosed with
hypertension
Requests for tests Blood pressure determination in the last six months in individuals diagnosed
with hypertension
Albumin-to-creatinin ratio or microalbuminuria test performed in the last
year in individuals diagnosed with hypertension
Electrocardiogram obtained in the last two years in individuals diagnosed
with hypertension
Drug prescription
adequacy
Justiﬁed indication of pharmacologic treatment for hypertension in
individuals diagnosed with this disorder in the follow-up
Adequacy of antihypertensive drug selection
Changes in FP attitude after CPG recommendation on hypertension
treatment
Changes in FP attitude after CPG alert on hypertension treatment
CPG, clinical practice guideline.
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improve or modify their behaviour simply because
they are aware the records are being studied. However,
the exhaustive, broad anddiverse sample of FPs included
in our study (> 3500) will minimise the potential bias
and will make our results more relevant and general-
isable. Additionally, socio-economic variables of the
patient or community are not considered in this study.
However, economic diﬀerences are minimised be-
cause the National Health Service in Spain ensures
universal coverage of the population.
The study also has unique strengths in addition to
the representativeness of the patient population and
the comprehensive access to FP data. All decisions in
the implementation of e-CPGs in the Catalan Institute
of Health were taken by expert consensus and the
methodology used is replicable. Finally, the adherence
to e-CPGs may not only reduce clinical practice
variability but point-of-care access to the supporting
evidence could also be an eﬀective educational inter-
vention for providers and patients.
Summary
This study has been designed to evaluate the imple-
mentation of three e-CPGs for the control of clinical
variables, diagnosis, treatment and management of
three major cardiovascular risk factors: hypercholes-
terolaemia, diabetes mellitus type 2 and hypertension.
Several clinical implications may derive from the
potential results. First, a new hypothesis regarding
the strategies for implementation of e-CPGs will be
generated. In addition, since individual data are available
from every FP, we will be able to detect speciﬁc
problems in CPG implementation. Second, this pro-
ject will shed light on needs for discussion, education
and use of evidence-based medicine to improve clini-
cal practice of FPs. Finally, to know the eﬀect of our
actions on patients and on National Health System
sustainability, assessment programmes such as the one
described in this protocol should be evaluated. If a
positive eﬀect is observed from this analysis, such as an
increase in the control of hypercholesterolemia, dia-
betes mellitus type 2 and hypertension, a reduction in
non-recommended drugs and an eﬃcient use of
complementary tests, this model of e-CPGs could be
extended to other regions in Spain or to other coun-
tries with electronic medical records systems. The ﬁrst
results of this study should be ready in late 2013.
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Table 6 Indicators of use of electronic clinical practice guidelines
Indicators per family
practitioner
Explanation
Patients adhered to CPG Percentage of patients for whom the family practitioner has accessed CPG
Entries to CPG Total number of entries to CPG
Entries to diﬀerent
algorithms
Number of individual entries to diagnosis, treatments and monitoring
support algorithms
Entries to all algorithms Total number of entries to all algorithms in the CPG
Entries to
recommendations
Total number of recommendations accepted for diagnosis and treatment
Changes after entry to
CPG recommendations
Total number of patients for whom the family practitioner has accepted any
CPG recommendation
Bad control alerts or lack
of monitoring
Number of bad-control alerts registered
CPG, clinical practice guideline.
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